TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02965703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood, urine, stool, and rectal swab samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood, urine, stool, and rectal swab samples

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood, urine, stool, and rectal swab samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectal Biopsy
Description: Undergo rectal biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectal Biopsy
Description: Undergo rectal biopsy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Rectal Biopsy
Description: Undergo rectal biopsy
Study: NCT00647842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Transdermal System 25 mcg/h + Bioclusive Overlay
Description: single application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Transdermal System 25 mcg/h
Description: single application
Study: NCT02848846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Hand
Description: The patients will use the robotic hand for a period of one year that will be divided in 3 different phases. The first phase is the intensive phase where the patient will use the robotic hand from Monday to Friday all days. This phase will last 6 weeks. The second phase is the semi-intensive where the patient will use the robotic hand only two days per week. This phase will last 6 weeks. The third phase is the monitoring where the patient will use the robotic hand only one day per week until the end of the trial.~During this phases the patient will perform different task requiring the use of the robotic hand.
Study: NCT01883882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: opioid taper support
Description: Weekly visits with physician's assistant (supervised by pain physician/psychiatrist and pain psychologist) who provides pharmacological and psychological support for opioid taper at 10% per week
Study: NCT00602862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 200 mg 2dd2 po for 4 weeks before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 200 mg 2dd2 po for 4 weeks before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111Indium-bevacizumab
Description: 100 MBq / 1 mg 111Indium/bevacizumab iv

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 111Indium-bevacizumab
Description: 100 MBq / 1 mg 111Indium/bevacizumab iv
Study: NCT00400946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: asparaginase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study: NCT00602862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111Indium-cG250
Description: 100 MBq / 10 mg 111Indium-cG250 iv
Study: NCT03630640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: Intravenous Nivolumab 240 Q2W neoadjuvant Intravenous Nivolumab 480 mg Q4W- adjuvant up to 12 months after EP
Study: NCT03633643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets)
Description: five oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets) at the evening of the surgery and thereafter twice daily on day~1 and 2 after surgery while the patient is in hospital.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral applications of Placebo
Description: five oral applications of Placebo at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
Study: NCT03201328

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Audio-vestibular examination
Description: Vestibular tests (videonystagmoscopy and head video impulse test), the tonal and vocal audiogram and the localigramme to the cochlear implanted subjects. Tonal audiometry and localigramme to the healthy subjects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audio-vestibular examination
Description: Vestibular tests (videonystagmoscopy and head video impulse test), the tonal and vocal audiogram and the localigramme to the cochlear implanted subjects. Tonal audiometry and localigramme to the healthy subjects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audio-vestibular examination
Description: Vestibular tests (videonystagmoscopy and head video impulse test), the tonal and vocal audiogram and the localigramme to the cochlear implanted subjects. Tonal audiometry and localigramme to the healthy subjects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Videonystagmoscopic study
Description: Rotating sound stimulation on a rotatory armchair and a laborer of Fukuda with sound stimulation and questionary before and after examination.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videonystagmoscopic study
Description: Rotating sound stimulation on a rotatory armchair and a laborer of Fukuda with sound stimulation and questionary before and after examination.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videonystagmoscopic study
Description: Rotating sound stimulation on a rotatory armchair and a laborer of Fukuda with sound stimulation and questionary before and after examination.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Posturographies study
Description: (stabilometry, sensory preferences, indications of energy consumption) with stereophonic stimulation and questionnaire before and after the examination.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posturographies study
Description: (stabilometry, sensory preferences, indications of energy consumption) with stereophonic stimulation and questionnaire before and after the examination.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posturographies study
Description: (stabilometry, sensory preferences, indications of energy consumption) with stereophonic stimulation and questionnaire before and after the examination.
Study: NCT02817542

Intervention type: DEVICE
Intervention: percutaneous coronary intervention
Description: Percutaneous coronary intervention. Procedures include: Implantation of stents The thrombus aspiration (TA) will be started before crossing the coronary atherosclerosis lesion. A minimum of two syringes (40 mL) of aspirate will be recommended. The guide catheter will be engaged with the coronary ostia when removing the thrombectomy catheter. The guide catheter will be aspirated after thrombectomy to avoid embolisation of air or thrombus. PCI procedure will be done without thrombectomy as per the investigator. Direct stenting will not be mandated in either treatment group. Bailout thrombectomy will be allowed after a failure of the initial PCI alone strategy. The decision about bailout thrombectomy will be made by the interventional cardiologist performing the initial PCI.

Intervention type: DEVICE
Intervention: percutaneous coronary intervention
Description: Percutaneous coronary intervention. Procedures include: Implantation of stents The thrombus aspiration (TA) will be started before crossing the coronary atherosclerosis lesion. A minimum of two syringes (40 mL) of aspirate will be recommended. The guide catheter will be engaged with the coronary ostia when removing the thrombectomy catheter. The guide catheter will be aspirated after thrombectomy to avoid embolisation of air or thrombus. PCI procedure will be done without thrombectomy as per the investigator. Direct stenting will not be mandated in either treatment group. Bailout thrombectomy will be allowed after a failure of the initial PCI alone strategy. The decision about bailout thrombectomy will be made by the interventional cardiologist performing the initial PCI.
Study: NCT01236222

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycling to school
Description: Regular cycling to school
Study: NCT05416606

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transurethral bipolar enucleation and resection of the prostate
Description: transurethral bipolar enucleation and resection of the prostate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open surgical transvesical prostatectomy
Description: open surgical transvesical prostatectomy
Study: NCT01380756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1- Dose Escalation
Description: AMG 900 is a small molecule aurora kinase inhibitor. AMG 900 will be administered daily for 4 days every 2 weeks or daily 7 days every 2 weeks (ie.g., 4 consecutive days of dosing followed by 10 consecutive days off treatment).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 2- Dose Expansion
Description: AMG 900 is a small molecule aurora kinases inhibitor. The dose expansion phase would be conducted to gain further clinical experience with AMG 900 in AML at the optimal dose schedule.
Study: NCT03025191

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speaker/Listener technique
Description: Couple will learn taking turns as the speaker and as the listener who paraphrases the speaker's point.The couple will then identify an issue they have faced in their relationship and will role-play using the technique to discuss it.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: Identification of and mapping sources of social support and the types of support provided by members of the network. Participants will also identify the strengths and weaknesses of their support network and think through ways to strengthen those networks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-Solving
Description: Couple will be taught steps to systematically analyze a problem and brainstorm solutions through a short video. Steps include identify the trigger/problem; identify the goal for addressing the problem; brainstorm possible solutions for each partner; evaluate the solutions and pick the best; and act on the best solution.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Setting
Description: Couple will be introduced to the concept of short- and long-term goal setting, including components of goal and planning for potential barriers. The couple will then set a goal for themselves that incorporates the skills obtained during the intervention, such as strengthening ties in their social support network. Participants will fill in a worksheet outlining their goal, potential barriers, and solutions to those barriers.
Study: NCT03687177

Intervention type: OTHER
Group type: OTHER
Intervention: With visual cue and nurses informed
Description: Using visual cue or no visual cue with to estimate the angle of elevation of the head of intubated patients with prevention of nurse

Intervention type: OTHER
Group type: OTHER
Intervention: Without visual cue and nurses informed
Description: Not using visual cue or no visual cue with to estimate the angle of elevation of the head of intubated patients with prevention of nurse
Study: NCT00675285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast sodium
Description: one tablet 5 mg once/day for 4 weeks
Study: NCT01272219

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Liraglutide placebo, subcutaneous (under the skin) injection once daily for 160 weeks.
Study: NCT00214526

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty with the Alair System
Description: Conventional therapy with ICS+LABA plus bronchial thermoplasty with the Alair System.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy with ICS+LABA
Description: Conventional therapy with ICS+LABA.
Study: NCT03729141

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Added Cholesterol
Description: Participants assigned to the added cholesterol group will receive snacks containing added cholesterol (1g/day) for 3 weeks prior to surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Added Cholesterol
Description: Participants assigned to the no added cholesterol group will receive snacks containing no added cholesterol for 3 weeks prior to surgery.
Study: NCT03375164

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: delandistrogene moxeparvovec
Description: Single IV infusion of delandistrogene moxeparvovec.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: delandistrogene moxeparvovec
Description: Single IV infusion of delandistrogene moxeparvovec.
Study: NCT00400946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexrazoxane hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mercaptopurine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IV
Study: NCT00994487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Energy Density Preload
Description: Each child with a parent will attend a lunch session. In these sessions children will drink a liquid preload that is high in energy density and then they will consume an ad libitum lunch. The ad libitum lunch will be videotaped, and the videotapes will be coded for parental feeding styles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Energy Density Preload
Description: Each child with a parent will attend a lunch session. In these sessions children will drink a liquid preload that is low in energy density and then they will consume an ad libitum lunch. The ad libitum lunch will be videotaped, and the videotapes will be coded for parental feeding styles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Energy Density Preload
Description: Each child with a parent will attend a lunch session. In these sessions children will drink a liquid preload that is low in energy density and then they will consume an ad libitum lunch. The ad libitum lunch will be videotaped, and the videotapes will be coded for parental feeding styles.
Study: NCT03735810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBS-008
Description: LBS-008 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBS-008
Description: LBS-008 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBS-008
Description: LBS-008 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBS-008
Description: LBS-008 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBS-008
Description: LBS-008 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBS-008
Description: LBS-008 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBS-008
Description: LBS-008 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBS-008
Description: LBS-008 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBS-008
Description: LBS-008 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Oral capsules
Study: NCT01238783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension
Description: Topical ocular dosed 3 times per day for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-15469A 0.5%
Description: Topical ocular dosed 3 times per day for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-6515 0.3%
Description: Topical ocular dosed 3 times per day for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical ocular dosed 3 times per day for 3 days
Study: NCT00619476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn 1200mg/day
Description: gabapentin enacarbil 1200mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn 2400mg/day
Description: gabapentin enacarbil 2400mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn 3600mg/day
Description: gabapentin enacarbil 3600mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT01300429

Intervention type: GENETIC
Intervention: obtain tissue specimens
Description: One core biopsy specimen will be placed in formalin and processed for cytogenetic and FISH analyses as well as DNA for ALK sequencing. The second core biopsy specimen will be immediately frozen in liquid nitrogen and stored in a -80 degree freezer for research specimen. Collection will be performed on-site at the time of the procedure.
Study: NCT02259920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KUC 7483 CL, immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUC 7483 CL, particulate formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUC 7483 CL, particulate formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUC 7483 CL, solution formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUC 7483 CL, solution formulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enterion™ capsule

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enterion™ capsule

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enterion™ capsule

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enterion™ capsule
Study: NCT01336062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoparticle Albumin-Bound Paclitaxel
Description: this study evaluate 3 dose level of nab-paclitaxel:100 mg /m2;125 mg /m2;80 mg /m2;
Study: NCT02169830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nortriptyline
Description: The nortriptyline will be given in an escalating fashion, starting at 25 mg PO qhs for 2 weeks, followed by 50 mg PO qhs for 2 weeks, and finally 75 mg PO qhs. Patients will be encouraged to use the lowest effective dose and to self-titrate their medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: Topiramate dosing will be 25 mg PO qhs for 1 week, followed by 25 mg BID for 1 week, followed by 25 mg in the morning and 50 mg qhs for 1 week, and finally 50 mg BID

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diet Modification
Description: Emphasis will be given to cessation of known migraine triggers such as caffeine, sodas, chocolates, alcohol (especially red wine) and aged cheeses. Patients who have complete control of their symptoms with diet and behavior modification alone will be followed for a total of 4 months to determine the durability of symptom relief.
Study: NCT00968838

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: White Blood Cell Transfusion
Description: 4 Transfusions, each taking approximately 1 hour:~Patients \<50 years of age receive 4 standard transfusions before they are randomized to receive further radiated or non radiated transfusions.~Patients \>50 years of age are randomized to receive either radiated or non radiated transfusions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: White Blood Cell Transfusion
Description: 4 Transfusions, each taking approximately 1 hour:~Patients \<50 years of age receive 4 standard transfusions before they are randomized to receive further radiated or non radiated transfusions.~Patients \>50 years of age are randomized to receive either radiated or non radiated transfusions.
Study: NCT00742885

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
Description: All subjects will receive 2 doses administered as an intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
Description: All subjects will receive 2 doses administered as an intramuscular (IM) injection.